Managing the infectious complications associated with pentostatin (Nipent), used alone or in combination with other agents in patients with low-grade lymphomas, poses a significant problem for clinicians. Since there is limited
Robert Drapkin, MD
Advertisement
Articles by Robert Drapkin, MD
Both pentostatin (Nipent) and rituximab (Rituxan) have single-agent activity in B-cell malignancies, including indolent and intermediate-grade non-Hodgkin’s lymphoma (NHL). Pentostatin is also active in pretreated patients
Advertisement
Latest Updated Articles
- Infectious Complications of Pentostatin Therapy
Published: June 1st 2000 | Updated:
- Pentostatin and Rituximab in the Treatment of Patients With B-Cell Malignancies
Published: June 1st 2000 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA OKs Subcutaneous Amivantamab in EGFR+ NSCLC
2
Imlunestrant Combo Will Not Be Pursued for FDA Approval in Breast Cancer
3
FDA Grants Regular Approval to Rucaparib in Metastatic CRPC
4
Pelareorep Exhibits Activity in Second-Line KRAS-Mutated Metastatic CRC
5